HIV-1 and other retroviruses occasionally undergo a high rate of G-to-A substitutions, a phenomenon named hypermutation. APOBEC3G, a dominant-acting host restriction factor, is packaged into virions in the absence of HIV-1 Vif expression. The cytidine deaminase activity of APOBEC3G deaminates cytidines in HIV-1 minus-strand DNA, leading to G-to-A hypermutation. The HIV-1 Vif protein binds to APOBEC3G and induces its proteasomal degradation, thereby preventing its incorporation into HIV-1 virions.Using mutational analysis, we showed that a single amino acid (D128K) is responsible for the species specificity of APOBEC3G proteins. The D128 residue either directly interacts with Vif or is involved in conformational changes that occur upon Vif binding. To gain insights into the mechanism by which APOBEC3G inhibits HIV-1 replication, we recently developed a sensitive cytidine deamination assay using scintillation proximity beads. Using this assay, we demonstrated that interactions with viral and nonviral RNAs that are packaged are sufficient for APOBEC3G virion incorporation and that interactions with viral proteins are not essential for virion incorporation. We are determining the stoichiometry of APOBEC3G in HIV-1 virions produced in primary CD4+ T cells in the absence of Vif expression. We are carrying out biochemical and genetic studies to elucidate the structure and function of APOBEC3G. We are purifying APOBEC3G to characterize its interactions with DNA, RNA, and other proteins. We are also carrying out mutational studies to characterize the domains of APOBEC3G and Vif that interact, and domains that are critical for its virion incorporation. We are developing high-throughput assays for the Vif-APOBEC3G interaction to identify small molecule inhibitors that block the ability of Vif to overcome APOBEC3G antiviral activity. In collaboration with Dr. Steven Zeichner, we are analyzing the effect of HIV-1 Vpr on transcriptional regulation of APOBEC3G. TRIM5alpha is a host restriction factor that targets the HIV-1 capsid, and inhibits viral replication in restricted cells. The mechanism by which TRIM5alpha inhibits viral replication is not understood. We are collaborating with Matt Stremlau and Dr. Joseph Sodroski to understand the effects of TRIM5alpha on HIV-1 reverse transcription. We are using the novel strand-specific amplification assay (SSA) that we have developed to determine the stage at which reverse transcription is inhibited by TRIM5alpha. Host restriction genes like APOBEC3G and TRIM5alpha suppress HIV-1 replication and act as dominant-acting inhibitors of HIV-1 replication. In contrast to the restriction genes, there are host genes that are used by HIV-1 to facilitate its replication. Because mammalian cells are diploid, it has been difficult to identify the recessive host genes that facilitate HIV-1 replication by mutational inactivation of the gene because it is necessary to inactivate both copies of the gene of interest. We are developing novel genetic screens to identify host genes that facilitate HIV-1 replication.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010595-02
Application #
7292871
Study Section
(RML)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Paprotka, Tobias; Venkatachari, Narasimhan J; Chaipan, Chawaree et al. (2010) Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol 84:5719-29
LaRue, Rebecca S; Andresdottir, Valgerdur; Blanchard, Yannick et al. (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83:494-7
Perkovic, Mario; Schmidt, Stanislaw; Marino, Daniela et al. (2009) Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J Biol Chem 284:5819-26
Russell, Rebecca A; Pathak, Vinay K (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81:8201-10
Boyko, Vitaly; Leavitt, Maria; Gorelick, Robert et al. (2006) Coassembly and complementation of Gag proteins from HIV-1 and HIV-2, two distinct human pathogens. Mol Cell 23:281-7
Fu, William; Dang, Que; Nagashima, Kunio et al. (2006) Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol 80:1242-9
Svarovskaia, Evguenia S; Xu, Hongzhan; Mbisa, Jean L et al. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279:35822-8
Xu, Hongzhan; Svarovskaia, Evguenia S; Barr, Rebekah et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 101:5652-7